九州通(600998.SH):匯添富九州通醫藥REIT完成發售
格隆匯2月12日丨九州通(600998.SH)公佈,2025年2月12日,匯添富九州通醫藥REIT完成發售,後續將在上海證券交易所上市,交易代碼爲508084,基金場內簡稱爲“九州通R”,擴位簡稱爲“匯添富九州通醫藥REIT”。
匯添富九州通醫藥REIT最終募集基金份額4億份,發售價格爲2.895元/份,基金募集資金總額爲人民幣11.58億元。其中,網下投資者認購數量爲0.70億份,佔發售份額總數的17.50%,有效認購倍數達50倍;公衆投資者認購數量爲0.30億份,佔發售份額總數的7.50%,有效認購倍數達1,192倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.